XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.26.1

Note 13 - Divestitures | 3 Months Ended
--- | ---
Mar. 31, 2026
Notes to Financial Statements |
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] | NOTE 13. DIVESTITURES On January 17, 2025, the Company completed the sale of its eyecare products sold under the Avenova brand and related assets (the “Avenova Asset Divestiture”) to PRN Physician Recommended Nutriceuticals, LLC for a base purchase price of $11.5 million, subject to customary post-closing adjustments. The Company recorded a gain of $10.7 million on the Avenova Asset Divestiture during the quarter ended March 31, 2025. Separately, on January 8, 2025, the Company completed the sale of two of its wound care trademarks to PhaseOne Health LLC (the “PhaseOne Divestiture”) for a purchase price of $500,000 and recorded a net gain of $0.5 million during the quarter ended March 31, 2025. Additional information regarding the terms of these transactions is included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024. In accordance with ASC 205-20, the results of operations and cash flows of the Avenova Asset Divestiture and the PhaseOne Divestiture have been excluded from continuing operations and presented as discontinued operations for all periods presented. The components of discontinued operations for the three months ended March 31, 2025 are summarized below (in thousands): Results of operations
|  | Avenova |  |  | PhaseOne |  |  | Total |
Net sales |  | $ | 433 |  |  | $ | 122 |  |  | $ | 555 |
Cost of goods sold |  |  | 170 |  |  |  | 75 |  |  |  | 245 |
Gross profit |  |  | 263 |  |  |  | 47 |  |  |  | 310 |
Operating expenses |  |  |  |  |  |  |  |  |  |  |  |
Sales and marketing |  |  | 224 |  |  |  | — |  |  |  | 224 |
Research and development |  |  | — |  |  |  | 3 |  |  |  | 3 |
Total operating expenses |  |  | 224 |  |  |  | 3 |  |  |  | 227 |
Operating income |  |  | 39 |  |  |  | 44 |  |  |  | 83 |
Gain on divestiture |  |  | 10,700 |  |  |  | 500 |  |  |  | 11,200 |
Net income from discontinued operations before income taxes |  |  | 10,739 |  |  |  | 544 |  |  |  | 11,283 |
Provision for income taxes |  |  | 269 |  |  |  | 14 |  |  |  | 283 |
Net income from discontinued operations, net of taxes |  | $ | 10,470 |  |  | $ | 530 |  |  | $ | 11,000 |
Cash flows from discontinued operations
|  | Avenova |  |  | PhaseOne |  |  | Total |
Operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Net income from discontinued operations |  | $ | 10,470 |  |  | $ | 530 |  |  | $ | 11,000 |
Adjustments to reconcile net income to net cash used in operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Non-cash gain on divestiture |  |  | (10,700 | ) |  |  | (500 | ) |  |  | (11,200 | )
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  | (72 | ) |  |  | 6 |  |  |  | (66 | )
Inventory |  |  | 73 |  |  |  | 43 |  |  |  | 116 |
Prepaid expenses and other current assets |  |  | — |  |  |  | — |  |  |  | — |
Other assets |  |  | 9 |  |  |  | — |  |  |  | 9 |
Accounts payable and accrued liabilities |  |  | (252 | ) |  |  | (38 | ) |  |  | (290 | )
Net cash (used in) provided by operating activities, discontinued operations |  |  | (472 | ) |  |  | 41 |  |  |  | (431 | )
Investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from divestiture |  |  | 11,000 |  |  |  | 500 |  |  |  | 11,500 |
Net cash provided by investing activities, discontinued operations |  |  | 11,000 |  |  |  | 500 |  |  |  | 11,500 |
Net increase in cash and cash equivalents, discontinued operations |  | $ | 10,528 |  |  | $ | 541 |  |  | $ | 11,069 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent + Details
Name: | us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration